A head-to-head clinical study found PSMA PET/CT detected bone metastases far more accurately than conventional bone scintigraphy in 108 prostate cancer patients, with both tested SUVmax thresholds performing similarly. The result supports PSMA PET/CT as a more sensitive tool for staging decisions when bone involvement drives treatment choice. The threshold parity suggests the imaging community may refine adoption around operational cutoffs without changing core clinical performance. Confirmatory work will likely be needed in broader populations and across different scan protocols.